On January 24, 2023 ATUM, a global specialist and industry leader in bioengineering solutions, reported the signing of a full licensing agreement for the Leap-In Transposase technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines (Press release, ATUM, JAN 24, 2023, View Source [SID1234626522]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, ATUM will provide Codiak access to its Leap-In Transposase technology to generate mammalian cells expressing exosomes engineered to deliver therapeutic payloads. The Leap-In technology is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-based mechanism for efficient insertion of genetically stable elements into the genome.
Scott Estes, Ph.D., VP of Cell Line Development at Codiak, said, "Through years of rigorous research and clinical validation we have created a platform for engineering and manufacturing therapeutic exosomes with various payloads on the surface or inside the lumen. We believe ATUM’s transposase technology has the potential to effectively synergize with Codiak’s engEx Platform to further enhance loading these vesicles, making them more potent and reducing cost of goods."
Claes Gustafsson, Ph.D., Chief Commercial Officer and Co-Founder at ATUM, commented, "Exosomes are bio vesicles that have the potential to fundamentally change drug delivery. We are proud and excited to license the Leap-In Transposase technology to Codiak for the engineering of cell lines that enables rapid and robust production of exosomes."